Announcing a Unique C-code for a Genentech BioOncology(R) product
- October 5, 2016
- Administrative, Clinical Practice Updates, Drugs, News
The following is important information regarding a unique C-code that was recently assigned to TECENTRIQ™ (atezolizumab) by the Centers for Medicare & Medicaid Services (CMS). The C-code for TECENTRIQ is C9483 (Injection, atezolizumab, 10 mg).
The unique C-code goes into effect on October 1, 2016. Payers may require its use until a permanent J-code is assigned. The permanent J-code is expected to be available for use starting on January 1, 2018.
The C-code is used primarily in the Medicare hospital outpatient setting. However, some payers accept this C-code instead of unclassified J- or C-codes when billing for TECENTRIQ. Please check with your payers to verify codes and special billing requirements.
The TECENTRIQ Billing and Coding Flash Card, which contains additional information about coding and billing, is attached to this email.
Please feel free to reach out if you have any questions. Additionally, you can seek assistance from one of the dedicated Specialists at TECENTRIQ Access Solutions at (888) 249‐4918, or visit Genentech-Access.com/TECENTRIQ for more information.
Click here for prescribing information
